Get the Stockscreener App
2.13
4.93%
0.10
Nrx Pharmaceuticals Inc stock is traded at $2.13, with a volume of 435.75K.
It is up +4.93% in the last 24 hours and down -33.64% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$2.03
Open:
$2
24h Volume:
435.75K
Relative Volume:
0.93
Market Cap:
$59.85M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.5325
EPS:
-4
Net Cash Flow:
$-21.66M
1W Performance:
-14.46%
1M Performance:
-33.64%
6M Performance:
-19.01%
1Y Performance:
+73.17%
1-Day Range:
$1.99
$2.16
1-Week Range:
$1.99
$2.49
52-Week Range:
$1.15
$6.01
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.13 | 57.04M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Buy |
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
Is NRx Pharmaceuticals Inc. Equity Warrant stock a top momentum playJuly 2025 Sentiment & Risk Controlled Stock Pick Alerts - newser.com
Is NRx Pharmaceuticals Inc. stock in correction or buying zoneInsider Selling & Consistent Profit Alerts - newser.com
What analysts say about NRx Pharmaceuticals Inc Equity Warrant stockAnalyst Downgrades & Affordable Portfolio Building - earlytimes.in
NRx Pharmaceuticals stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Nigeria
NRx Pharmaceuticals stock maintains Buy rating at H.C. Wainwright - Investing.com
How buybacks impact NRx Pharmaceuticals Inc. Equity Warrant stock valueJuly 2025 Reactions & Accurate Buy Signal Alerts - newser.com
Using data filters to optimize entry into NRx Pharmaceuticals Inc. Equity WarrantGold Moves & Technical Entry and Exit Tips - newser.com
Will NRx Pharmaceuticals Inc. stock benefit from upcoming earnings reportsTrade Volume Summary & Weekly Top Gainers Alerts - newser.com
Market reaction to NRx Pharmaceuticals Inc.’s recent newsAnalyst Upgrade & Free High Accuracy Swing Entry Alerts - newser.com
Is NRx Pharmaceuticals Inc. forming a bottoming baseQuarterly Profit Summary & High Accuracy Swing Trade Signals - newser.com
Analyzing recovery setups for NRx Pharmaceuticals Inc. investorsWeekly Profit Recap & Free Safe Entry Trade Signal Reports - newser.com
What hedge fund activity signals for NRx Pharmaceuticals Inc. stockRate Cut & Community Trade Idea Sharing - newser.com
Is now a turning point for NRx Pharmaceuticals Inc. Equity Warrant2025 Momentum Check & Real-Time Market Trend Scan - newser.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: NRX Pharmaceuticals (NRXP), LifeMD (LFMD) and Hims & Hers Health (HIMS) - The Globe and Mail
How to forecast NRx Pharmaceuticals Inc. trends using time seriesJuly 2025 Trade Ideas & Long-Term Growth Portfolio Plans - newser.com
How to track smart money flows in NRx Pharmaceuticals Inc.2025 Technical Overview & Safe Capital Growth Tips - newser.com
NRx Pharmaceuticals’ Earnings Call: Optimism Amid Challenges - TipRanks
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2025 Earnings Call Transcript - Insider Monkey
NRx Pharmaceuticals Reports Q3 2025 Financial Results - TipRanks
Pattern recognition hints at NRx Pharmaceuticals Inc. upsideSwing Trade & Real-Time Volume Triggers - newser.com
NRx Pharmaceuticals (NRXP) Reports Q3 Results and Advances NRX-100 and NRX-101 Regulatory Programs - NewMediaWire
NRX Pharmaceuticals Inc (NRXP) Q3 2025 Earnings Call Highlights: Strategic Clinic Expansion and ... By GuruFocus - Investing.com Canada
Earnings call transcript: NRX Pharmaceuticals Q3 2025 highlights innovation and market challenges - Investing.com Nigeria
Three Revenue-Generating Facilities in Florida Plus Six More by Year-End in Expanding $750 Million Market Suicidal Depression Market: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Markets Financial Content
NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q3 Results and Advances NRX-100 and NRX-101 Regulatory Programs - TipRanks
NRXP: First revenue reported, drug pipeline advanced, and cash secured for growth through 2026 - TradingView
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):